Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.61 |
| ▸ | TSHR | P16473 | 5/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.59 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4861758 | 0.87 | SMN1; SMN2 (0.72) | SMN1; SMN2KDM4EHSD17B10TSHRALDH1A1 | |
| SCHEMBL14857060 | 0.83 | KDM4E (0.59) | SMN1; SMN2KDM4EHSD17B10ALDH1A1LMNA | |
| SCHEMBL14857407 | 0.83 | TSHR (0.63) | SMN1; SMN2KDM4EHSD17B10TSHRALDH1A1 | |
| SCHEMBL14855872 | 0.82 | KDM4E (0.64) | SMN1; SMN2KDM4EHSD17B10TSHRALDH1A1 | |
| SCHEMBL7633248 | 0.82 | KDM4E (0.69) | SMN1; SMN2KDM4EHSD17B10TSHRALDH1A1 | |
| SCHEMBL1281444 | 0.82 | SMN1; SMN2 (0.69) | SMN1; SMN2KDM4EHSD17B10TSHRALDH1A1 | |
| SCHEMBL1039949 | 0.82 | KDM4E (0.69) | SMN1; SMN2KDM4EHSD17B10TSHRALDH1A1 | |
| SCHEMBL7628954 | 0.82 | KDM4E (0.69) | SMN1; SMN2KDM4EHSD17B10TSHRALDH1A1 | |
| SCHEMBL7632095 | 0.82 | KDM4E (0.69) | SMN1; SMN2KDM4EHSD17B10TSHRALDH1A1 | |
| SCHEMBL14855680 | 0.82 | KDM4E (0.76) | SMN1; SMN2KDM4EHSD17B10TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993622-B2 | Antiviral compounds | EIRIUM AB (SE) | 2015-03-31 | — | — | US | claimed |
| US-20130210915-A1 | ANTIVIRAL COMPOUNDS | EIRIUM AB (SE) | 2013-08-15 | — | — | US | claimed |
| EP-2580190-A1 | NEW ANTIVIRAL COMPOUNDS | Wadell, Göran (SE) | 2013-04-17 | — | — | EP | disclosed |
| WO-2011155898-A1 | NEW ANTIVIRAL COMPOUNDS | WADELL GOERAN (SE) | 2011-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210915-A1 | ANTIVIRAL COMPOUNDS | MAVS, ZC3HAV1, EIF2AK2 | SMN1; SMN2 3366/4885KDM4E 2866/4885HSD17B10 2926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.